Dyne Therapeutics (DYN) Share-based Compensation (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Share-based Compensation of $15.0 million for Q2 2026, up 42.32% year-over-year from $10.5 million in Q2 2025, and up 14.49% quarter-over-quarter from $13.1 million in Q1 2026.
Dyne Therapeutics (DYN) Share-based Compensation (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Share-based Compensation for 8 consecutive years, with $15.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation rose 42.32% year-over-year to $15.0 million; the TTM figure through Jun 2026 stood at $49.8 million (up 16.46% YoY), while the FY2025 annual figure was $64.9 million, down 10.73% from the prior year.
- Share-based Compensation rose to $15.0 million in Q2 2026 per DYN's latest filing, from $13.1 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $66.0 million in Q3 2025 and bottomed at $3.0 million in Q2 2022.
- Historically, Share-based Compensation has averaged $11.7 million across 5 years, with a median of $7.7 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 36.27% — and 2025, when it jumped 654.72%.
- Dyne Therapeutics' Share-based Compensation stood at $3.8 million in 2022, then jumped by 49.53% to $5.7 million in 2023, then jumped by 82.84% to $10.5 million in 2024, then advanced by 7.15% to $11.2 million in 2025, then surged by 33.4% to $15.0 million in 2026.
- Business Quant data shows DYN's Share-based Compensation at $15.0 million in Q2 2026, $13.1 million in Q1 2026, and $11.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 14.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.98 Mn |
| Jun 30, 2026 | 14.98 Mn |
| Mar 31, 2026 | 13.08 Mn |
| Mar 31, 2026 | 13.08 Mn |
| Dec 31, 2025 | 11.23 Mn |
| Dec 31, 2025 | 11.23 Mn |
| Sep 30, 2025 | 66.00 Mn |
| Sep 30, 2025 | 66.00 Mn |
| Jun 30, 2025 | 10.52 Mn |
| Jun 30, 2025 | 10.52 Mn |
| Mar 31, 2025 | 13.02 Mn |
| Mar 31, 2025 | 13.02 Mn |
| Dec 31, 2024 | 10.48 Mn |
| Dec 31, 2024 | 10.48 Mn |
| Sep 30, 2024 | 8.75 Mn |
| Sep 30, 2024 | 8.75 Mn |
| Jun 30, 2024 | 6.74 Mn |
| Jun 30, 2024 | 6.74 Mn |
| Mar 31, 2024 | 19.91 Mn |
| Mar 31, 2024 | 19.91 Mn |